Limits

The federal Medicare program finalized a plan to restrict coverage for Biogen’s Alzheimer’s therapy to patients in certain clinical trials, while offering a road map to cover drugs that show clinical benefit in the disease. The decision announced on Thursday will effectively prevent most patients with Alzheimer’s disease from receiving […]